Paul Workman, The Institute of Cancer Research, London, UK
James Downing

Paul Workman PhD FRCS FMedSci is from July 1st 2014 Interim Chief Executive at The Institute of Cancer Research (ICR), London and Director of Cancer Research UK Cancer Therapeutics Unit – the largest non-profit cancer drug discovery group worldwide. Paul is a pioneer in the discovery of molecularly targeted cancer therapies, having been responsible for over 20 drugs entering the clinic. He is especially renowned for the discovery and molecular pharmacology of HSP90 and PI3 kinase inhibitors and as the originator of the widely used Pharmacological Audit Trail for biomarker-led drug development. Paul was a scientific founder of Piramed Pharma and Chroma Therapeutics. Paul has won numerous honours, including Fellow of the Academy of Medical Sciences; Fellow of the Royal Society of Chemistry; Fellow of the European Academy of Cancer Sciences; Cancer Research UK Life Fellow; AACR Team Science Award (Leader); Cancer Research UK Translational Cancer Research Prize; Raymond Bourgine Award for Achievement in Cancer Research; and the George and Christine Sosnovsky Award in Cancer Therapy and Chemistry World Entrepreneur of the Year Award, both from the Royal Society of Chemistry.

Website: www.icr.ac.uk/research/team_leaders/Workman_Paul/ | Twitter: @ICRnews
Facebook: www.facebook.com/theinstituteofcancerresearch

« Go Back

Supporting Publications
Cancer Cell
Trends in Pharmacological Sciences
Trends in Molecular Medicine
Cell Reports
Cancer Therapeutics
In partnership with
  • CAMS
  • CSCO
Platinum Sponsor
Gold Sponsor
Silver Sponsors
  • Haihe
  • Huawei
  • Janssen
  • Perkinelmer
  • Seahorse Bioscience
  • SIMM
  • Sino Biological
  • Tekon
  • ThermoFisher
  • Tissue Gnostics
  • CAMS
  • CSCO